Axa cut its holdings in TESARO Inc (NASDAQ:TSRO) by 2.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 118,182 shares of the biopharmaceutical company’s stock after selling 3,267 shares during the quarter. Axa owned about 0.22% of TESARO worth $9,793,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of TSRO. Nationwide Fund Advisors grew its position in shares of TESARO by 63.1% in the 3rd quarter. Nationwide Fund Advisors now owns 61,500 shares of the biopharmaceutical company’s stock valued at $7,940,000 after purchasing an additional 23,800 shares during the period. Crossmark Global Holdings Inc. acquired a new position in shares of TESARO in the 3rd quarter valued at approximately $230,000. State Board of Administration of Florida Retirement System grew its position in shares of TESARO by 1.2% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 49,054 shares of the biopharmaceutical company’s stock valued at $6,333,000 after purchasing an additional 570 shares during the period. Gabelli Funds LLC acquired a new position in shares of TESARO in the 3rd quarter valued at approximately $426,000. Finally, American Century Companies Inc. grew its position in shares of TESARO by 50.9% in the 3rd quarter. American Century Companies Inc. now owns 5,826 shares of the biopharmaceutical company’s stock valued at $752,000 after purchasing an additional 1,965 shares during the period.
In other news, SVP Martin H. Jr. Huber sold 1,803 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $54.86, for a total transaction of $98,912.58. Following the sale, the senior vice president now owns 11,647 shares in the company, valued at approximately $638,954.42. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Timothy R. Pearson sold 2,575 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $54.86, for a total value of $141,264.50. Following the sale, the chief financial officer now owns 7,303 shares in the company, valued at approximately $400,642.58. The disclosure for this sale can be found here. In the last quarter, insiders have bought 334,913 shares of company stock worth $19,083,294 and have sold 13,042 shares worth $760,526. Corporate insiders own 34.60% of the company’s stock.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.96). TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. The company had revenue of $48.02 million for the quarter, compared to the consensus estimate of $51.78 million. research analysts forecast that TESARO Inc will post -9.54 earnings per share for the current year.
TSRO has been the subject of several research analyst reports. Leerink Swann upgraded TESARO from a “market perform” rating to an “outperform” rating in a research report on Wednesday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $158.00 price objective on shares of TESARO in a research report on Monday, November 20th. Argus set a $154.00 price objective on TESARO and gave the company a “buy” rating in a research report on Tuesday, November 28th. Citigroup reiterated a “buy” rating and issued a $135.00 price objective (down from $216.00) on shares of TESARO in a research report on Wednesday, December 20th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $80.00 price objective on shares of TESARO in a research report on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $133.39.
WARNING: This piece was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/03/13/tesaro-inc-tsro-shares-sold-by-axa.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.